WHICH TREATMENT SHOULD BE SELECTED FOR THE OPTIMUM APPROACH TO PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH DRIVER MUTATION? A CASE REPORT AND LITERATURE REVIEW

We present a case of concomitant c-ros oncogene 1 insert ignore into journalissuearticles values(ROS1); and anaplastic lymphoma kinase insert ignore into journalissuearticles values(ALK); and fusion in non small cell lung cancer insert ignore into journalissuearticles values(NSCLC); in a 59-year-old patient and review the treatment efficacy of co-mutations. The choice of the treatment and its effectiveness with rare co-mutations is a subject of considerable interest. This review will provide clues to the optimal treatment approach to NSCLC patients with more than one driver mutations. However, randomized studies are needed to clarify which patients with concurrent mutations may benefit from chemotherapy or related tki.